L-Dopa prodrugs: An overview of trends for improving parkinson's disease treatment

Current Pharmaceutical Design

Volumn 17, Issue 32, 2011, Pages 3482-3493

  Di Stefano, Antonio ^a   Sozio, Piera ^a   Cerasa, Laura Serafina ^a   Iannitelli, Antonio ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Antiparkinson; Codrugs; Dopamine; L dopa; Parkinson's disease; Prodrugs

Indexed keywords

3 (3 HYDROXY 4 PIVALOYLOXYPHENYL)ALANINE; AMIDE; ESTER DERIVATIVE; LEVODOPA; LEVODOPA METHYL ESTER; PRODRUG;

ARTICLE; CHEMICAL MODIFICATION; DRUG BIOAVAILABILITY; DRUG METABOLISM; HUMAN; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

ANIMALS; DRUG DESIGN; HUMANS; LEVODOPA; MOLECULAR STRUCTURE; PARKINSON DISEASE; PRODRUGS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 82055208103     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211798194495     Document Type: Article

References (83)

1. Abou-Sleiman PM, Muqit, MMK, Wood NW. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat Rev Neurosci 2006; 7: 207-19.
2. Blandini F, Greenamyre JT. Protective and Symptomatic Strategies for Therapy of Parkinson's. Drugs Today 1999; 35: 473-83.
3. Bodor N, Farag HH. Improved delivery through biological membranes. 13. Brain specific delivery of dopamine with a dihydropyridine- pyridinium salt type redox delivery system. J Med Chem 1983; 26: 528-34.
4. Kao HD, Traboulsi A, Itoh S, Dittert L, Hussain A. Enhancement of the Systemic and CNS Specific Delivery of L-Dopa by the Nasal Administration of Its Water. Soluble Prodrugs. Pharmaceut Res 2000; 17: 978-84.
5. Standaert D, Young A. Treatment of Central Nervous System Degenerative Disorders. In Gilman AG, Hardman JG, Limbird LE, Molinoff PB, Ruddon RW. The Pharmacological Basis of Therapeutics. Ed. McGraw Hill, New York 1996.
6. Hagan JJ, Middlemiss DN, Sharpe PC, Poste, GH. Parkinson's disease: prospects for improved drug therapy. TIPS 1997; 18: 156-63.
7. Sasahara K, Nitanai T, Habara T, Morioka T, Nakajimai E. Dosage form design for improvement of bioavailability of levodopa III: Influence of dose on pharmacokinetic behaviour of levo-dopa administration in dogs and parkinsonian patients. J Pharm Sci 1980; 69: 1374-8.
8. Nutt JG, Woodward WR, Anderson JL. The Effect of carbidopa on the pharmacokinetics of intravenously administered levodopa: The mechanism of action in the treatment of parkinsonism. Annal Neurol 1986; 18: 537-43.
9. Wingard LB, Brody TM, Larner J, Schwartz A. HumanPharmacology. St. Louis: Mosby 1991.
10. Cedarbaum JM. Antiparkinsonian drugs. Clin Pharmacokin 1987; 13: 141-78.
11. Nutt JG, Woodward WR. Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients. Neurology 1986; 36: 739-44.
12. Hardie R, Lees AJ, Stern GM. On-off fluctuations in parkinson's disease. Brain 1984; 107: 487-506.
13. Quinn N, Parkes JD, Marsden CD. Control of on/off phenomenon by continuous intravenous infusion of levodopa. Neurology 1984; 34: 1131-6.
14. Sasahara K, Nitanai T, Habara T, Morioka T, Kawahara Y, Nakajima E. Dosage form design for improvement of bioavailability of levodopa IV: Possible causes of low bioavailability of oral levodopa in dogs. J Pharm Sci 1981; 70: 730-3.
15. Hutton JH, Morris JL, Gustavo CR. Treatment of chronic parkinson's disease with controlled-release carbidopa/ levodopa. Neurology 1988; 45: 861-4.
16. Bordor N, Sloan KB, Higuchi T, Sasahara K. Improved delivery through biological membranes 4: Prodrugs of L-dopa. J Med Chem 1977; 20: 1435-45.
17. Goole J, Vanderbist F, Amighi K. Development and evaluation of new multiple-unit levodopa sustained-release floating dosage forms. Int J Pharm 2007; 334: 35-41.
18. Di Stefano A, Mosciatti B, Cingolani GM, et al. Dimeric L-Dopa derivatives as potential prodrugs. Bioorg Med Chem Lett 2001; 11: 1085-8.
19. Hauser RA. Early Pharmacologic Treatment in Parkinson's Disease. Am J Manag Care 2010; 16: S100-7.
20. Di Stefano A, Sozio P, Iannitelli A, Cerasa SL. New drug delivery strategies for improved Parkinson's disease therapy. Expert Opin Drug Deliv 2009; 6(4): 389-404.
21. Carlsson A, Lindqvist M, Magnusson T. 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 1957; 180(1200): 33.
22. Birkmayer W, Hornykiewicz O. The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia. Wien Klin Wochenschr 1961; 10: 787-8.
23. Outeiro TF, Ferreira J. Current and future therapeutic strategies for Parkinson's disease. Curr Pharm Des 2009; 15(34): 3968-76.
24. Rautio J, Kumpulainen H, Heimbach T, et al. Prodrugs: design and clinical applications. Nat Rev Drug Discov 2008; 7: 255-70.
25. Marrel C, Boss G, Van De Waterbeemd H, et al. L-Dopa esters as potential prodrugs. Eur J Med Chem.-Chim Ther 1985; 20: 459-65.
26. Cooper DR, Marrel C, Van De Waterbeemd H, et al. L-Dopa methyl ester-a candidate for chronic systemic delivery of L-Dopa in Parkinson's disease. Clin Neuropharmacol 1984; 89-98.
27. Garzon-Aburbeh A, Poupaert JH, Claesen M, Dumont P. A lymphotropic prodrug of L-dopa: synthesis, pharmacological properties, and pharmacokinetic behavior of 1,3-dihexadecanoyl-2-[(S)-2- amino-3-(3,4-dihydroxyphenyl)propanoyl] propane-1,2,3-triol. J Med Chem 1986; 29: 687-91.
28. Cooper DR, Marrel, C, Van De Waterbeemd H, Testa B, Jenner P, Marsden CD. L-dopa esters as potential prodrugs: effect on brain concentration of dopamine metabolites in reserpinized mice. J Pharm Pharmacol 1987; 39: 809-18.
29. Cooper DR, Marrel C, Van De Waterbeemd H, Testa B, Jenner P, Marsden CD. L-dopa esters as potential prodrugs: behavioural activity in experimental models of Parkinson's disease. J Pharm Pharmacol 1987; 39: 627-35.
30. Ihara M, Tsuchiya Y, Sawasaki Y, et al. New potential prodrug to improve the duration of L-dopa: L-3-(3-hydroxy-4- pivaloyloxyphenyl)alanine. J Pharm Sci 1989; 78: 525-9.
31. Ihara M, Nakajima S, Hisaka A, et al. Hydrolysis and acyl migration of a catechol monoester of L-dopa: L-3-(3-hydroxy-4- pivaloyloxyphenyl)alanine. J Pharm Sci 1990; 79: 703-8.
32. Ishikura T, Senou T, Ishihara H, Kato T, Ito T. Drug delivery to the brain. DOPA prodrugs based on a ring-closure reaction to quaternary thiazolium compounds. Int J Pharm 1995; 116: 51-63.
33. Tang S, Martinez LJ, Sharma MA, Chai M. Synthesis and characterization of water-soluble and photostable L-DOPA dendrimers. Org Lett 2006; 8: 4421-4.
34. Xiang JN, Zhou CX, Yao F, Nguyen MQ, Inventors; Xenoport Inc., assignee. Catechol protected levodopa diester prodrugs, compositions, and methods of use. World Intellectual Property Organization WO 2008/079387. 2008 Jul.
35. Stein G, Nudelman A, Rephaeli A, Gil-Ad I, Weizman A, Inventors; Ramot At Tel Aviv University Ltd, Bar-Ilan University, Biolinerx Ltd. Novel conjugates for treating neurodegenerative diseases and disorders. World Intellectual Property Organization 2009 Aug.
36. Hobbs C, Inventor; Proximagen Ltd. Amino Acid Derivatives. World Intellectual Property Organization WO2009/022098A1. 2009 Feb.
37. Denora N, Laquintana V, Lopedota A, et al. Novel L-Dopa and Dopamine Prodrugs Containing a 2-Phenyl imidazopyridine Moiety. Pharm Res 2007; 24(7): 1309-24.
38. Daniel A, Albanese A, Gainotti G, Gregari B, Bartolomeo P. Zolpidem in Parkinson's disease. Lancet 1997; 349: 1222-3.
39. Zhou T, Hider RC, Jenner P, et al. Design, synthesis and biological evaluation of L-dopa amide derivatives as potential prodrugs for the treatment of Parkinson's disease. Eur J Med Chem 2010; 45: 4035-42.
40. Jiang W, Lv L, Zhou S, et al. Simultaneous determination of l-dopa and its prodrug (S)-4-(2-acetamido-3-ethoxy-3-oxopropyl)-1,2- phenylene diacetate in rat plasma by high-performance liquidchromatography-tandem mass spectrometry and its application in a pharmacokinetic study. J Pharm Biomed Anal 2010; 53: 751-4.
41. Atlas D, inventor; Yissum research development company of the Hebrew university of Jerusalem, assignee. L-Dopa Amide derivatives and uses thereof. World intellectual property organization WO 2004/069146. 2004 Aug.
42. Santus G, Del Soldato P, Sparatore A, inventors; CTG Pharma srl, assignee. Pharmaceutical composition for the treatment of neurodegenerative diseases. World intellectual property organization WO 2009/156466. 2009 Dec.
43. Felix AM, Winter DP, Wang SS, et al. Synthesis and antireserpine activity of peptides of L-Dopa. J Med Chem 1974; 17: 422-6.
44. Horst WD, Pool WR, Spiegel HE. Correlation between brain dopamine levels and 1-dopa activity in anti-Parkinson tests. Eur J Pharmacol 1973; 21(3): 337-42.
45. Wang H, Lee J, Tsai M, Lu H, Hsu W. Synthesis and Pharmacological activities of a novel tripeptide mimetic dopamine prodrug. Bioorg Med Chem Lett 1995; 5: 2195-8.
46. Bai JPF. pGlu-L-Dopa-Pro: a tripeptide prodrug targeting the intestinal peptide transporter for absorption and tissue enzymes for conversion. Pharm Res 1995; 12: 1101-4.
47. Bai JPF, Hu M, Subramanian P, Mosberg HI, Amidon GL. Utilization of peptide carrier system to improve intestinal absorption: targeting prolidase as a prodrug-converting enzyme. J Pharm Sci 1992; 81: 113-6.
48. Polt R, Porreca F, Szabò LZ, Bilsky EJ. Glycopeptide enkephalin analogues produce analgesia in mice: evidence for penetration of the blood brain barrier. Proc Natl Acad Sci USA. 1994; 91: 7114-8.
49. Chavis C, Grodenic F, Imbach JL. Ribosides et dérivés de la Lméthyl dopa et de la L-dopa. Eur J Med Chem-Chim Ther 1981; 16: 219-27.
50. Bonina F, Puglia C, Rimoli MG, et al. Glycosyl derivatives of dopamine and L-dopa as anti-Parkinson prodrugs: synthesis, pharmacological activity and in vitro stability studies. J Drug Target 2003; 11(1): 25-36.
51. Yoon S, Fulton DB, Robyt JF. Synthesis of dopamine and LDOPA-α-glycosides by reaction with cyclomaltohexaose catalyzed by cyclomaltodextrin glucanyltransferase. Carbohydr Res 2009; 344: 2349-56.
52. Langlois M, Quintard D, Abalain C. Synthesis of symmetrical pseudopeptides as potential inhibitors of the human immunodeficiency virus-1 protease. Eur J Med Chem 1994; 29: 639-47.
53. Christiaans JAM, Timmerman H. Cardiovascular hybrid drugs: combination of more than one pharmacological property in one single molecule. Eur J Pharm Sci 1996; 4: 1-22.
54. Mahfouz NM, Aboul-Fadl T, Diab AK. Metronidazole twin ester prodrugs: synthesis, physicichemical properties, hydrolysis kinetics and antigiardial activity. Eur J Med Chem 1998; 33: 675-83.
55. Giannola LI, Giammona G, Alotta R. Pro-drugs of isoniazid: synthesis and diffusion characteristics of acyl derivatives. Pharmazie 1992; 47: 423-5.
56. Ducho C, Görbig U, Jessel S, Gisch N, Balzarini J, Meier C. BiscycloSal- d4T-monophosphates: drugs that deliver two molecules of bioactive nucleotides. J Med Chem 2007; 50: 1335-46.
57. Cannazza G, Di Stefano A, Mosciatti B, et al. Detection of levodopa, dopamine and its metabolites in rat striatum dialysates following peripheral administration of l-DOPA prodrugs by mean of HPLC-EC. J Pharm Biomed Anal 2005; 36: 1079-84.
58. Di Stefano A, Carafa M, Sozio P, et al. Evaluation of rat striatal ldopa and DA concentration after intraperitoneal administration of ldopa prodrugs in liposomal formulations. J Control Release 2004; 99: 293-300.
59. Di Stefano A, Sozio P, Iannitelli A, Marianecci C, Santucci E, Carafa M. Maleic- and fumaric-diamides of (O,O-diacetyl)-LDopa- methylester as anti-Parkinson prodrugs in liposomal formulation. J Drug Target 2006; 14: 652-61.
60. Wang Y, Liu ZZ, Chem SZ. Synthesis of a Dopamimetic Thionated Dipeptide Prodrug of L-DOPA. Chin Chem Lett 2005; 16: 713-5.
61. Cingolani GM, Di Stefano A, Mosciatti B, et al. Bioorg Med Chem Lett 2000; 10: 1385-8.
62. Giorgioni G, Claudi F, Ruggieri S, et al. Design, synthesis and preliminary pharmacological evaluation of new imidazolinones as L-DOPA prodrugs. Bioorg Med Chem 2010; 18: 1834-43.
63. Rasmussen GJ, Bundgaard H. Prodrugs of peptides. 15. 4- Imidazolidinone prodrug derivatives of enkephalins to prevent aminopeptidase-catalyzed metabolism in plasma and absorptive mucosae. Int J Pharm 1991; 76: 113-22.
64. Menger FM, Rourk MJ. Synthesis and Reactivity of 5- Fluorouracil/Cytarabine Mutual Prodrugs. J Org Chem 1997; 62: 9083-8.
65. Cavalli A, Bolognesi ML, Minarini A, et al. Multi-target-Directed Ligands To Combat Neurodegenerative Diseases. J Med Chem 2008; 51(3): 347-72.
66. Singh G, Sharma PD. Mutual prodrugs: a recent trend in prodrug design. Indian J Pharm Sci 1994; 56: 69-79.
67. Savolainen J, Leppänen J, Forsberg M, et al. Synthesis and in vitro/ in vivo evaluation of novel oral N-alkyl and N,N-dialkylcarbamate esters of entacapone Life Sci 2000; 67: 205.
68. Leppanen J, Huuskonen J, Nevalainen T, Gynther J, Taipale H, Jarvinen T. Design and Synthesis of a Novel L-Dopa-Entacapone Codrug. J Med Chem 2002; 45: 1379-82.
69. Di Stefano A, Sozio P, Iannitelli A, Cocco A, Orlando G, Ricciutelli M. Synthesis and Preliminary Evaluation of LDopa/ Benserazide Conjugates as Dual Acting Codrugs. Lett Drug Des Discov 2006; 3: 747-52.
70. Sayre LM, Smith MA, Perry G. Chemistry and Biochemistry of Oxidative Stress in Neurodegenerative Disease. Curr Med Chem 2001; 8: 721-8.
71. Asanuma M, Miyazaki I, Ogawa N. Dopamine- or L-DOPAinduced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease. Neurotox Res 2003; 5: 165-76.
72. Du F, Qian ZM, Zhu L, et al. L-DOPA Neurotoxicity is mediated by up regulation of DMT12IRE expression. PLoS ONE 2009; 4: e4593.
73. Rosini M, Andrisano V, Bartolini M, et al. Rational Approach to discover multipotent anti-Alzheimer drugs. J Med Chem 2005; 48: 360-3.
74. Bharath S, Cochran BC, Hsu M, Ames BN, Andersen JK. Pretreatment with R-Lipoic acid alleviates the effects of GSH depletion in PC12 cells: implications for Parkinson's disease therapy. Neurotoxicology 2002; 23: 479-86.
75. Di Stefano A, Sozio P, Cocco A, et al. L-Dopa and DA/(R)-α- lipoic acid conjugates as multifunctional codrugs with antioxidant properties. J Med Chem 2006; 49: 1486-93.
76. Ley JP, Bertram HJ. Synthesis of lipophilic clovamide derivatives and their antioxidative potential against lipid peroxidation. J Agric Food Chem 2003; 51(16): 4596-602.
77. Sozio P, Iannitelli A, Cerasa LS, et al. New L-Dopa Codrugs as Potential Antiparkinson Agents. Arch Pharm Chem Life Sc 2008; 341: 412-7.
78. Michiels C, Raes M, Toussaint O, Remacle J. Importance of Seglutathione peroxidase, catalase, and Cu/Zn-SOD for cell survival against oxidative stress. Free Radic Biol Med 1994; 17(3): 235-48.
79. Pinnen F, Cacciatore I, Cornacchia C. et al. Synthesis and Study of L-Dopa-Glutathione Codrugs as New Anti-Parkinson Agents with Free Radical Scavenging Properties. J Med Chem 2007; 50: 2506-15.
80. Bobrowski K, Hug GL, Pogocki D, Marciniak B, Schöneich C. Sulfur radical cation-peptide bond complex in the one-electron oxidation of S-methylglutathione. J Am Chem Soc 2007; 129: 9236-45.
81. Pinnen F, Cacciatore I, Cornacchia C, et al. CNS delivery of LDopa by a new Hybrid Glutathione-Methionine peptidomimetic prodrug. Amino Acid DOI 10.1007/s00726-010-0804-z.
82. Pinnen F, Cacciatore I, Cornacchia C, et al. Codrugs Linking LDopa and Sulfur-Containing Antioxidants: New Pharmacological Tools against Parkinson's Disease. J Med Chem 2009; 52: 559-63.
83. Minelli A, Conte C, Prudenzi E, et al. N-Acetyl-L-Methionyl-LDopa- Methyl Ester as a dual acting drug that relieves L-Dopainduced oxidative toxicity. Free Radic Biol Med 2010; 49: 31-9.